Olema Pharmaceuticals (OLMA) Expected to Announce Quarterly Earnings on Tuesday
by Scott Moore · The Cerbat GemOlema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.
Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01. On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Olema Pharmaceuticals Price Performance
NASDAQ OLMA traded down $0.24 on Tuesday, reaching $14.39. 382,120 shares of the company’s stock traded hands, compared to its average volume of 1,448,195. Olema Pharmaceuticals has a 12 month low of $3.89 and a 12 month high of $36.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.95 and a quick ratio of 9.95. The stock has a 50-day simple moving average of $17.14 and a 200 day simple moving average of $20.16. The stock has a market cap of $1.25 billion, a PE ratio of -7.74 and a beta of 2.05.
Analyst Upgrades and Downgrades
OLMA has been the topic of several recent analyst reports. Wolfe Research initiated coverage on shares of Olema Pharmaceuticals in a report on Friday, March 27th. They issued a “peer perform” rating on the stock. Oppenheimer restated an “outperform” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Stifel Nicolaus initiated coverage on shares of Olema Pharmaceuticals in a report on Wednesday, February 11th. They issued a “buy” rating and a $48.00 target price on the stock. The Goldman Sachs Group cut their target price on shares of Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Tuesday, April 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $44.40.
Read Our Latest Stock Analysis on OLMA
Insider Activity at Olema Pharmaceuticals
In other news, insider Shawnte Mitchell sold 25,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total transaction of $606,250.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 16.36% of the company’s stock.
Hedge Funds Weigh In On Olema Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the business. Invesco Ltd. increased its position in shares of Olema Pharmaceuticals by 25.0% during the 4th quarter. Invesco Ltd. now owns 155,732 shares of the company’s stock valued at $3,893,000 after purchasing an additional 31,098 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of Olema Pharmaceuticals during the 4th quarter valued at about $250,000. Vestal Point Capital LP purchased a new stake in shares of Olema Pharmaceuticals during the 4th quarter valued at about $41,250,000. Wellington Management Group LLP increased its position in shares of Olema Pharmaceuticals by 8.2% during the 4th quarter. Wellington Management Group LLP now owns 220,971 shares of the company’s stock valued at $5,524,000 after purchasing an additional 16,764 shares during the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in shares of Olema Pharmaceuticals during the 4th quarter valued at about $4,143,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.
About Olema Pharmaceuticals
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.